Sanofi draws fire over cost of MS drug Lemtrada
PARIS (Reuters) – Medical journal The Lancet warned that Sanofi’s experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators.
October 31st, 2012
Posted in
Drug